SM
BPMC

Sabby Management’s Blueprint Medicines BPMC Stock Holding History

Sabby Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,000
Closed -$5.42M – 298
2016
Q1 		$5.42M Hold
3,000
– – 0.27% 40
2015
Q4 		$7.9M Buy
+3,000
New +$67.5K 0.43% 39

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Sabby Management's BPMC Position: Q2 2017 in Review

Sabby Management sold out of Blueprint Medicines (BPMC) in Q2 2017, closing a stake of 50,000 shares — an estimated $2M sold.

Sabby Management first reported a position in BPMC in Q2 2015 and held it in 4 quarters. The position peaked at $8M in Q2 2015. 124 funds tracked by Wall St. Rank hold BPMC as of Q2 2017.

  • Sabby Management reported no remaining Blueprint Medicines position as of Q2 2017 after selling out during the quarter.
  • Sabby Management sold 50,000 Blueprint Medicines shares in Q2 2017, an estimated $2M.
  • Sabby Management first reported a position in Blueprint Medicines in Q2 2015 and held it in 4 quarters.
  • Sabby Management's Blueprint Medicines position peaked at $8M in Q2 2015.
  • 124 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.